A prospective study of metformin effectiveness as a mammalian target of rapamycin inhibitor and immunoregulator in women with polycystic ovarian syndrome
DOI:
https://doi.org/10.52783/jns.v14.1585Keywords:
PCOS, metformin, immunomodulation, mTOR, TGFβ1, IL6Abstract
Background
Polycystic ovarian syndrome (PCOS) is a common disorder affecting ovary function. it’s thought that an autoimmune regulatory mechanism could mediate its onset. Metformin is an effective medication for PCOS treatment and is proposed to act as an immunoregulatory drug.
Objective
The present work aimed to study the effectiveness of metformin as a mammalian target of rapamycin (mTOR) inhibitor and immunoregulator in PCOS women.
Subjects and Methods
A total of 80 blood samples were collected, 30 of them from newly diagnosed PCOS women. Once more, blood samples were taken from them following 500 mg of metformin treatment period. In addition, 20 healthy women enrolled as a control group. The levels of mTOR, IL6, and TGFβ1 were measured using the ELISA technique.
Results
The present work showed that after metformin treatment, levels of mTOR and TGFβ1 dropped significantly, but IL6 levels remained constant. Patients on longer-term metformin treatment experienced a significant decrease in mTOR and TGFβ1 levels, but TGFβ1 remained higher than in healthy controls. No significant differences were found in IL6 levels between treatment duration groups and the body mass index (BMI) groups, according to Spearman correlation, there were no correlation found between mTOR and other studied marker neither pre nor post treatment groups.
Conclusion
This study concluded that metformin has pleiotropic effects on immune reprogramming due to its role as an mTOR inhibitor and immune modulation of regulatory cytokines.
Downloads
Metrics
References
Deswal R, Narwal V, Dang A, Pundir CS. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. Journal of Human Reproductive Sciences. 2020;13(4):261–71.
Shamsi M, Ghazavi A, Saeedifar AM, Mosayebi G, Pour SK, Ganji A. The immune system’s role in PCOS. Molecular biology reports. 2022 Nov;49(11):10689–702.
Shabbir S, Khurram E, Moorthi VS, Eissa YTH, Kamal MA, Butler AE. The interplay between androgens and the immune response in polycystic ovary syndrome. Journal of Translational Medicine [Internet]. 2023;21(1):1–26. Available from: https://doi.org/10.1186/s12967-023-04116-4
Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertility and Sterility. 2012;97(1):7–12.
Adamczak R, Ukleja-Sokołowska N, Lis K, Dubiel M. Function of follicular cytokines: Roles played during maturation, development and implantation of embryo. Medicina (Lithuania). 2021;57(11):1–10.
Johnson NP. Metformin use in women with polycystic ovary syndrome. Annals of Translational Medicine. 2014;2(6):1–6.
Attia GM, Almouteri MM, Alnakhli FT. Role of Metformin in Polycystic Ovary Syndrome (PCOS): Related Infertility. Cureus. 2023;15(8).
Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, et al. The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. European Journal of Endocrinology [Internet]. 2023;189(2):S38–64. Available from: https://doi.org/10.1093/ejendo/lvad098
Attia GM, Almouteri MM, Alnakhli FT. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. Cureus. 2023 Aug;15(8):e44493.
Amin S, Lux A, O’Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. British Journal of Clinical Pharmacology. 2019;85(1):37–46.
Roa J, Garcia-Galiano D, Varela L, Sánchez-Garrido MA, Pineda R, Castellano JM, et al. The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Endocrinology. 2009;150(11):5016–26.
Azziz R. Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2006;91(3):781–5. Available from: https://doi.org/10.1210/jc.2005-2153
Liu AL, Liao HQ, Li ZL, Liu J, Zhou CL, Guo ZF, et al. New insights into mTOR signal pathways in ovarian-related diseases: Polycystic ovary syndrome and ovarian cancer. Asian Pacific Journal of Cancer Prevention. 2016;17(12):5087–94.
Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, et al. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metabolism [Internet]. 2017;25(2):463–71. Available from: http://dx.doi.org/10.1016/j.cmet.2016.12.009
Essah PA, Apridonidze T, Iuorno MJ, Nestler JE. Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. Fertility and Sterility. 2006;86(1):230–2.
Lu X, Guo S, Cheng Y, Kim J-H, Feng Y, Feng Y. Stimulation of ovarian follicle growth after AMPK inhibition. Reproduction (Cambridge, England). 2017 May;153(5):683–94.
Jiang Z-Z, Hu M-W, Ma X-S, Schatten H, Fan H-Y, Wang Z-B, et al. LKB1 acts as a critical gatekeeper of ovarian primordial follicle pool. Oncotarget. 2016 Feb;7(5):5738–53.
Zhao Y, Zhang Y, Li J, Zheng N, Xu X, Yang J, et al. MAPK3/1 participates in the activation of primordial follicles through mTORC1-KITL signaling. Journal of cellular physiology. 2018 Jan;233(1):226–37.
Ren W, Yin J, Duan J, Liu G, Tan B, Yang G, et al. mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets. European Journal of Immunology. 2016;46(2):291–9.
Nagai S, Kurebayashi Y, Koyasu S. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Annals of the New York Academy of Sciences. 2013;1280(1):30–4.
Wisam A, Fadhil A, Nori W. Unveiling Systemic Immune Inflammation Index Correlations in Women with Polycystic Ovary Syndrome: A Cross-sectional Study. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) [Internet]. 2024;6(2):156–161. Available from: https://ajms.iq/index.php/ALRAFIDAIN/article/view/934
Saravia J, Raynor JL, Chapman NM, Lim SA, Chi H. Signaling networks in immunometabolism. Cell Research [Internet]. 2020;30(4):328–42. Available from: http://dx.doi.org/10.1038/s41422-020-0301-1
Xu B, Dai W, Liu L, Han H, Zhang J, Du X, et al. Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway. Endocrine Journal. 2022;69(7):863–75.
Cheng TYD, Omilian AR, Yao S, Sanchez P V., Polk LZ, Zhang W, et al. Body fatness and mTOR pathway activation of breast cancer in the Women’s Circle of Health Study. npj Breast Cancer [Internet]. 2020;6(1):1–9. Available from: http://dx.doi.org/10.1038/s41523-020-00187-4
Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017 Mar;168(6):960–76.
Tsenkova P, Robeva R, Elenkova A, Zacharieva S. Prevalence and Characteristics of the Polycystic Ovarian Syndrome in Overweight and Obese Premenopausal Women. Acta Endocrinologica. 2022;18(4):417–23.
Abdulrahman Z, Atrakji M, Al-Maliky A, Hussein K, Hussain S. The association of metformin dose up-titration and treatment duration with adiposity, lipid profile indicators, and serum leptin levels in T2DM Iraqi patients. Journal of Health Sciences. 2023;
Qamar U, Atkin SL, Sathyapalan T. Obesity and Polycystic Ovary Syndrome. Practical Guide to Obesity Medicine. 2017;3(2):59–70.
Li Y, Cheng Y, Zhou Y, Du H, Zhang C, Zhao Z, et al. High fat diet-induced obesity leads to depressive and anxiety-like behaviors in mice via AMPK/mTOR-mediated autophagy. Experimental neurology. 2022 Feb;348:113949.
Banerjee S, Cooney LG, Stanic AK. Immune Dysfunction in Polycystic Ovary Syndrome. ImmunoHorizons. 2023;7(5):323–32.
Sakata N. The anti-inflammatory effect of metformin: The molecular targets. Genes to Cells [Internet]. 2024;29(3):183–91. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/gtc.13098
Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 2019 Nov;33(11):2695–709.
Lin YS, Tsai SJ, Lin MW, Yang CT, Huang MF, Wu MH. Interleukin-6 as an Early Chronic Inflammatory Marker in Polycystic Ovary Syndrome with Insulin Receptor Substrate-2 Polymorphism. American Journal of Reproductive Immunology. 2011;66(6):527–33.
Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AFH, Schill T, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. European Journal of Endocrinology. 2004;150(4):525–32.
Tumu VR, Govatati S, Guruvaiah P, Deenadayal M, Shivaji S, Bhanoori M. An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women. Journal of Assisted Reproduction and Genetics. 2013;30(12):1541–6.
Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecological Endocrinology. 2008;24(7):378–84.
Vasyukova E, Zaikova E, Kalinina O, Gorelova I, Pyanova I, Bogatyreva E, et al. Inflammatory and Anti-Inflammatory Parameters in PCOS Patients Depending on Body Mass Index: A Case-Control Study. Biomedicines. 2023;11(10):1–13.
Azziz R. Diagnosis of Polycystic Ovarian Syndrome : The Rotterdam Criteria Are Premature. 2006;91(3):781–5.
Al-Musawy SH, Al-Saimary IE, Flaifil MS. Levels of Cytokines Profile in Polycystic Ovary Syndrome. Medical Journal of Babylon [Internet]. 2018;15(2). Available from: https://journals.lww.com/mjby/fulltext/2018/15020/levels_of_cytokines_profile_in_polycystic_ovary.3.aspx
Peng Z, Sun Y, Lv X, Zhang H, Liu C, Dai S. Interleukin-6 Levels in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. PloS one. 2016;11(2):e0148531.
Xiao H, Zhang J, Xu Z, Feng Y, Zhang M, Liu J, et al. Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Scientific Reports [Internet]. 2016;6(January):1–9. Available from: http://dx.doi.org/10.1038/srep28597
Ramamoorthy S, Bhuvaneswari K. A Cross Sectional Study on the Status of Inflammatory Markers in Polycystic Ovary Syndrome (PCOS) in Indian Population. Biomedical and Pharmacology Journal [Internet]. 2019 May 11;12:1975+. Available from: https://link.gale.com/apps/doc/A628404734/AONE?u=anon~d8c0180b&sid=googleScholar&xid=3a66e2d7
Farhangi MA, Saboor-Yaraghi AA, Eshraghian M, Ostadrahimi A, Keshavarz SA. Serum transforming growth factor β (TGF-β) is associated with body mass index in healthy women. Acta Endocrinologica. 2013;9(3):361–8.
Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X, et al. Serum levels of TSP-1, NF-κB and TGF-β1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clinical Endocrinology. 2015;83(6):913–22.
Yadav H, Quijano C, Kamaraju AK, Gavrilova O, Malek R, Chen W, et al. Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metabolism [Internet]. 2011;14(1):67–79. Available from: http://dx.doi.org/10.1016/j.cmet.2011.04.01
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
